IM-1617

IM-1617 is a preclinical, potential first-in-class antibody-drug conjugate (ADC) developed by Immunome for the treatment of solid tumors. The drug targets an undisclosed receptor tyrosine kinase that is preferentially expressed in a broad array of solid tumors, including colorectal cancer, non-small cell lung cancer (NSCLC), breast, ovarian cancers, melanoma, and esophageal carcinoma. This receptor promotes tumor cell survival and mediates immune cell exclusion—suggesting both direct antitumor activity and possible immunomodulatory effects. IM-1617 consists of a proprietary antibody selected for high tumor binding with minimal normal tissue binding; it is conjugated via a cleavable linker to HC74, Immunome’s proprietary topoisomerase I inhibitor (TOP1i) payload designed for broad use in solid tumors. Preclinical studies have demonstrated robust antitumor activity with tumor regressions after single doses in multiple xenograft models. IND-enabling work began in late 2024.